Ensuring Study Integrity and Reliability During a Drug Recall: Technology and Services Delivered on Schedule
When clinical development teams hear the words “safety/drug recall,” tension immediately arises. Ensuring the safety of the patient and preventing the potential for unblinding is of the utmost importance. This case study uncovers the steps a Sponsor and their Interactive Response Technology partner took to ensure the study continued without unblinding, loss of patients, or delay.
You will learn:
- Ways to ensure patients are not dispensed the effected product
- Innovative strategies for dosing options to ensure unblinding doesn’t occur
- How to avoid delays due to insufficient supplies and preserve continuity of the study
Free Instant Access
*By submitting your information you acknowledge that you have read the privacy statement and you consent to our processing the data in accordance with that privacy statement. We may, from time to time, send you material relevant to your interests. If you change your mind at any time about wishing to receive material from us, you can send an email to [email protected]. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list.
